ALK to invest further in the world's first vaccine against peanut allergy
Summary: ALK buys additional shares in the French biotech company DBV Technologies and thus invests in the continued development of a new promising vaccine against peanut allergy, one of the most severe food allergies.
No hay comentarios:
Publicar un comentario